NanoViricides, Inc. (NNVC)
NYSE American · Healthcare · Biotechnology
$1.45+13.28%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $37.0M
- 52-week range
- $0.85 – $2.23
- 52-week change
- −11.72%
- EPS (trailing)
- −$0.41
- Analyst rating
- 1.0 Strong buy
Fiscal year to Jun 2026
- Revenue
- $0K
- Net income
- −$8.2M
- Diluted EPS
- −$0.41
- Free cash flow
- −$7.8M
From the company’s annual report on SEC EDGAR.
About NanoViricides, Inc.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
Headquarters: Shelton, United States · 7 employees · nanoviricides.com